Tru Niagen®, Consumer Product was Niagen Bioscience’s largest segment in fiscal 2025, bringing in $97.67M of $129.42M (75%).
| Subsegments | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Tru Niagen®, Consumer Product | $60.11M | $69.53M | $76.77M | $97.67M | ||||
| Tru Niagen Consumer Product | — | — | — | — | ||||
| Food-Grade Niagen® | — | $10.55M | $17.54M | $24.11M | ||||
| Niagen® Ingredient | $8.28M | — | — | — | ||||
| Niagen Ingredient | — | — | — | — | ||||
| Reference Standards | $3.08M | $2.80M | $2.89M | $3.00M | ||||
| Pharmaceutical-Grade Niagen® | — | — | $1.70M | $3.78M | ||||
| Other Ingredients | $456.00K | $587.00K | $574.00K | $781.00K | ||||
| Consulting & Other | $123.00K | $101.00K | $120.00K | $73.00K | ||||
| Total | $72.05M | $83.57M | $99.60M | $129.42M |
Niagen Bioscience brought in $129.42M from its six segments in fiscal 2025, the year ended December 31, 2025. That was up 29.9% from $99.60M in fiscal 2024. Tru Niagen®, Consumer Product was the largest at $97.67M (75.5%), ahead of Food-Grade Niagen® at $24.11M (18.6%) and Pharmaceutical-Grade Niagen® at $3.78M (2.9%). The other three segments brought in $3.86M combined.
Compared with fiscal 2024, Pharmaceutical-Grade Niagen® grew fastest, up 122.6% to $3.78M. Every segment above 2% of revenue grew.
Niagen Bioscience began breaking out Food-Grade Niagen® in fiscal 2023 and Pharmaceutical-Grade Niagen® in fiscal 2024. Niagen Bioscience stopped reporting Niagen® Ingredient as a separate segment after fiscal 2022, when it brought in $8.28M.
Consumer Products Segment was Niagen Bioscience’s largest segment in fiscal 2025, bringing in $97.67M of $129.42M (75%).
| Segment | FY 2011 | FY 2012 | FY 2015 | FY 2016 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Consumer Products Segment | $60.11M | $69.53M | $76.77M | $97.67M | ||||||||||
| Consumer Products | — | — | — | — | ||||||||||
| Ingredients Segment | $8.74M | $11.14M | $19.81M | $28.68M | ||||||||||
| Ingredients | — | — | — | — | ||||||||||
| Core Standards Contract Service & Ingredients | — | — | — | — | ||||||||||
| Core Standards Contract Services | — | — | — | — | ||||||||||
| Corestandardscontractservices | — | — | — | — | ||||||||||
| Analytical Reference Standards & Services Segment | $3.20M | $2.91M | $3.01M | $3.08M | ||||||||||
| Analytical Reference Standards & Services | — | — | — | — | ||||||||||
| Scientific Regulatory | — | — | — | — | ||||||||||
| Scientific & Regulatory Consulting Segment | — | — | — | — | ||||||||||
| Scientificregulatory | — | — | — | — | ||||||||||
| Retai Ldietary Supplement Products1 | — | — | — | — | ||||||||||
| Total | $72.05M | $83.57M | $99.60M | $129.42M |
Niagen Bioscience brought in $129.42M from its three segments in fiscal 2025, the year ended December 31, 2025. That was up 29.9% from $99.60M in fiscal 2024. Consumer Products Segment was the largest at $97.67M (75.5%), ahead of Ingredients Segment at $28.68M (22.2%) and Analytical Reference Standards & Services Segment at $3.08M (2.4%).
Compared with fiscal 2024, Ingredients Segment grew fastest, up 44.7% to $28.68M. Every segment above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these segments grew from $72.05M to $129.42M, a compound annual growth rate of 21.6%. Consumer Products Segment's share of the total fell from 83.4% to 75.5%.
Niagen Bioscience (NAGE) reports its revenue by subsegments and by segment. In fiscal 2025, Tru Niagen®, Consumer Product was its largest segment, bringing in $97.67M (75.5% of the total), followed by Food-Grade Niagen® at $24.11M (18.6%).
Tru Niagen®, Consumer Product was Niagen Bioscience's largest segment in fiscal 2025, bringing in $97.67M, or 75.5% of the $129.42M total across its six segments.
Among Niagen Bioscience's segments that make up at least 2% of revenue, Pharmaceutical-Grade Niagen® grew fastest in fiscal 2025, up 122.6% from $1.70M to $3.78M.
Every figure comes from Niagen Bioscience's annual financial filings, as reported. Each line keeps the name Niagen Bioscience gives it, and years follow its fiscal calendar.
Niagen Bioscience's revenue by subsegments goes back to fiscal 2018, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.